A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex
PHASE1CompletedINTERVENTIONAL
Enrollment
42
Participants
Timeline
Start Date
Not specified
Study Completion Date
May 31, 1990
Conditions
HIV Infections
Interventions
DRUG
Didanosine
Trial Locations (1)
14215
SUNY - Buffalo, Erie County Medical Ctr., Buffalo
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000710 - A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex | Biotech Hunter | Biotech Hunter